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INTRODUCTION
The best potentially curative therapy for malignant biliary 
obstruction is complete surgical resection.
1,2 Unfortunately, a 
majority of these patients with advanced cases are not good 
candidates for such curative therapy and may benefit from 
palliative therapy biliary drainage with stent placement is the 
treatment of choice for malignant biliary obstruction caused 
by unresectable neoplasms. Median survival of such patients 
is lower without biliary than with the biliary drainage,
3-5 and 
bacterial cholangitis or liver failure often contributes to death. 
The aims of palliation in these patients are to relieve the ob-
structive cholestasis and its associated morbidities like pruri-
tus, cholangitis and pain; to avoid liver failure due to progres-
sive biliary obstruction; and to improve quality of life, cost-
effectiveness, procedure-related complications and hospital 
stays through minimal invasive therapy.
6 Palliation of ob-
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structive cholestasis can be achieved successfully through 
two major non-surgical routes; one is a percutaneous route via 
percutaneous transhepatic cholangiography (PTC) and the 
other is an endoscopic route via endoscopic retrograde cholan-
gio-pancreatography (ERCP). 
Biliary drainage via the endoscopic route offers the advan-
tages of physiologic bile drainage and has been proved to be 
more non-invasive and comfortable for patients than that via 
the percutaneous route.
7,8 A major disadvantage of percuta-
neous drainage is the presence of a percutaneous tube, which 
could be uncomfortable for patients and cause tube related-
complications, such as hemorrhage, infection, bile le-akage, 
pleural complications, catheter blockage and migration. 
Therefore, in the palliation of malignant biliary obst-ruction, 
the endoscopic approach can be initially used with per-cutane-
ous radiological intervention reserved for any unexpect-ed fail-
ures. The strategy of palliative treatment differs according to the 
location (i.e., hilar or distal bile duct) of the malignant biliary 
stricture.
PALLIATION FOR MALIGNANT DISTAL 
BILE DUCT OBSTRUCTION 
The majority of distal bile duct obstructions are inopera-
ble, and therefore restoring biliary flow with relief of jaundice 
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and pruritus is the primary aim in the palliation of obstructive 
cholestasis due to distal lesions. Endoscopic biliary drainage 
with biliary stent placement has now become the main and 
least invasive palliative modality for achieving adequate symp-
tom relief, which has been proven to be more effective in >80% 
of cases with lower morbidity than surgery, and perhaps may 
provide a survival benefit in patients with obstructive cho-
lestasis due to unresectable malignant distal bile duct obstruc-
tions.
9 When it fails or is unable to be performed, percutane-
ous biliary drainage with or without percutaneous stenting 
may be a better choice as an alternative palliation of malig-
nant distal bile duct obstructions. Endoscopic route via ERCP 
in these patients has several advantages over percutaneous 
route via PTC. The duodenum and the papilla can be directly 
inspected to check for tumor infiltration under endoscopic 
view of ERCP, cytological or biopsy samples can be easily ob-
tained via endoscopic channel and subsequent placement of 
a biliary stent can be performed to relieve the obstructive cho-
lestasis. Therefore, most stents used on these patients are in-
serted endoscopically, although many non-comparative stud-
ies, assessing the outcomes, between percutaneous and endo-
scopic palliation for treatment of distal bile duct obstruction, 
stated that there were no significant differences in technical 
success, complication and mortality rates.
10-12
The two main types of commercially available biliary stents 
are plastic stents and self-expandable metal stents (SEMS). 
Biliary stents are inserted successfully in approximately 90% 
to 95% of patients with malignant distal bile duct obstructions 
and the procedure is more often successful in patients with dis-
tal rather than hilar lesions.
9 When contemplating endoscop-
ic palliation of obstructive jaundice, important variables that 
need to be considered include location and extent of the bili-
ary obstruction, potential need for repeated interventions, 
choice between plastic versus metal stents, and the life expectan-
cy of the patient.
13
Technique of endoscopic biliary stenting
Palliative drainage of malignant distal bile duct obstruction 
should be first attempted endoscopically. After cannulating the 
bile duct and injecting contrast medium under ERCP, careful 
consideration of biliary imaging allows detailed planning and 
successful execution of the palliative procedure. If endoscopic 
palliation of obstructive jaundice is considered, a decision 
should be made regarding the size and type of biliary stent. Re-
lief of jaundice due to malignant distal bile duct obstructions 
requires introduction of large 10 to 11.5 Fr plastic stents or SEMSs 
inserted with a duodenoscope using a 3.8 mm or 4.2 mm work-
ing channel. Initial insertion of a 10 Fr plastic stent is recom-
mended if the diagnosis of malignancy is not established or if 
expected survival is <4 months. Whatever stent is to be used, 
a standard 0.035-inch guidewire through the catheter is in-
serted across the stricture to be stented into the bile duct and 
its tip passed into an intrahepatic duct. Biliary sphincterotomy 
is not necessary for placement of a single plastic biliary stent 
or a SEMS in transpapillary position. It is nevertheless rou-
tinely performed before stenting by some endoscopists pos-
sibly in order to facilitate stent exchange during follow-up, or 
for cases requiring more than one biliary stent placement.
14 
While plastic stents are inserted using a three layer coaxial sys-
tem, consisting of guidewire, inner guiding catheter and 
pusher tube/stent, SEMSs are placed over the standard guide-
wire. The stents must be positioned and released accurately 
through the tumor under fluoroscopic and endoscopic guid-
ance. The distal part of the SEMS should protrude about 1 cm 
into the duodenum to allow easy endoscopic access, in case it 
is needed for the restoration of patency of occluded stents.
8 If 
conventional endoscopic stenting fails despite best efforts, 
PTC can then be performed for percutaneous biliary drainage 
with/without stenting or a percutaneous endoscopic biliary 
stenting for conversion into the endoscopic biliary drainage. 
Plastic versus metal stents
Both plastic stents and SEMSs can be used for the palliation 
of malignant distal bile duct obstructions. Plastic stents are 
relatively less expensive compared to SEMSs, and can be re-
moved and replaced easily if they become occluded. However, 
the diameter of plastic stents is limited up to 12 Fr by the work-
ing channel size of the duodenoscope. Plastic stents have li-
mited stent patency because they have relatively narrow lu-
men and easily become occluded with biliary sludge and/or 
bacterial biofilm comprising of protein, bilirubin, bacteria and 
amorphous debris.
15 Stent occlusion usually leads to recurrent 
biliary obstruction accompanying jaundice and/or ascending 
cholangitis. In case of cholangitis or decrease in total bilirubin 
level by <20% from baseline at 7 days post stent insertion, bili-
ary imaging or endoscopic revision should be considered.
14 
Plastic stents of 10 to 11.5 Fr have patency rates of approxima-
tely 3 months but smaller diameter stents have significantly lo-
wer patency rates and should not be routinely placed for palli-
ative drainage.
16 Plastic stents measuring no smaller than 10 
Fr in diameter and possibly certain stent designs, such as the 
DoubleLayer stent and stents with an anti-reflux valve, provide 
the longest biliary patency, but using a 11.5 Fr model or drug 
administration has not shown a more prolonged stent patency.
14 
Two strategies have been employed against to plastic stent 
occlusion, including management of management of expect-
ant episodes of stent occlusion and prophylactic scheduled 
exchange at 3-month intervals in order to prevent the risk of 
subsequent cholangitis. Prophylactic plastic stent changes im-
prove symptom-free survival compared to stent change at 78  Clin Endosc 2011;44:76-86
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signs of stent occlusion. However, with prophylactic plastic 
stent changes, patients who live more than 6 months are likely 
to be affected by the expenses and patient compliance for re-
peated stent changes is needed.
17
SEMSs were developed to overcome the diameter limita-
tion of plastic stents as they deliver stents with as larger di-
ameter as up to 30 Fr or 10 mm, when deployed, using a rela-
tively smaller delivery system of 7 to 8 Fr, facilitating easier 
passage across the biliary strictures. This larger diameter fa-
cilitates biliary flow and improves patency rates.
18 The com-
parison studies between plastic and SEMSs at ERCP con-
cluded that the patency rates of SEMSs were superior to those 
of plastic stents for distal biliary obstruction, with 10 to 12 
months vs. 3 to 4 months.
17-20 Because unresectable malignant 
biliary obstruction is typically associated with survival of less 
than one year, SEMSs are intended to yield palliation of ob-
structive symptoms throughout the remaining lifespan of 
these patients.
18,21,22 Although SEMSs are more expensive and 
there is no significant difference in the survival time between 
plastic and SEMSs, recent European Society of Gastrointesti-
nal Endoscopy guidelines recommend insertion of SEMS, 10 
mm in-diameter, in patients with an established diagnosis of 
malignancy as the prime stent, whether expected survival 
time is >4 months or if the cost of the SEMS itself is <50% than 
that of ERCP procedure.
14 This is due to superior stent paten-
cy, decreased need for repeated ERCP to manage recurrent 
jaundice, shorter hospital stays, reduced duration of antibiotic 
treatment, and fewer complications.
17,23 
Early complications develop in approximately 5% of pa-
tients after endoscopic biliary stenting is attempted, includ-
ing infection, pancreatitis and bleeding, regardless of the 
stent type used. Complications were distributed as follows: bi-
liary infection (35%), pancreatitis (29%), bleeding (23%), per-
foration (6%), early stent migration (3%), and renal failure 
(3%). Of the commercially available plastic biliary stents, Tef-
lon-made stents of the Tannenbaum or Amsterdam type result 
in a significantly lower short-term success rate, defined by de-
creasen levels of jaundice, serum bilirubin or pruritus, but si-
milar morbidity and 30 day mortality rate, as compared with 
polyethylene-made stents.
14 Late complications of biliary stent-
ing mostly consist of stent dysfunction, which is approximately 
twice more frequent with plastic stents compared to SEMS, fol-
lowed by much less frequent cholecystitis, duodenal perfora-
tion and bleeding ulcer. Approximately 5% of plastic stents 
and partially covered SEMS migrate while 1% of uncovered 
SEMS and 20% of fully covered SEMS migrate.
14 SEMSs may 
still eventually become occluded with tumor ingrowth, tumor 
overgrowth, epithelial hyperplasia or biliary sludge. Insertion 
of a second SEMS within the occluded SEMS yields a longer 
biliary patency than inserting a plastic stent, particularly if one 
of the two SEMSs (initially placed or placed for treating stent 
dysfunction) is a covered stent. However, in cases where the life 
expectancy is ≤3 months, insertion of a plastic stent would suf-
fice.
14 Another major limiting factor of uncovered SEMSs is 
that they cannot be removed any other way than by operation. 
So tissue confirmation of cancer should always be obtained 
before placement of the SEMSs.
24
Covered versus uncovered metal stents
Uncovered stents are made from stainless steel, cobalt bas-
ed alloy, or nickel- titanium (nitinol) alloy and are designed 
with a wire mesh. Covered stents were developed to overcome 
tumor ingrowth through the wire mesh and have non-porous 
covering membranes, such as polyurethane, silicone, or expand-
ed polytetrafluoroethylene. The covering may extend over the 
entire length of the stent (fully covered SEMS), or small areas 
at the ends may be left uncovered (partly covered SEMS). Al-
though they prevent tumor ingrowth, overgrowth still remains 
a problem. The long-term durability of the covering mem-
brane is sometimes problematic, because the covering mem-
branes can be damaged during deployment or degradation 
due to reflux of the duodenal and gastric juices.
25 Tumor in-
growth in patients using covered SEMSs has the possibility 
of occurring through the tear of the covered membranes. Oth-
er potential problems of the covered SEMSs include encrusta-
tion of bile, stent migration, or occlusion of the cystic duct, pan-
creatic duct, or lateral branches of the bile ducts. There was no 
significant difference in the incidence of cholecystitis between 
covered and uncovered SEMSs.
26-28 Neoplastic involvement of 
the cystic duct and gallbladder stones are the key risk factor 
for SEMS-related cholecystitis.
14 While several studies of cov-
ered SEMSs reported relatively high incidence of acute pan-
creatitis (5.6-6.1%),
26,29-31 recent analysis of prospective ran-
domized trials comparing covered and uncovered SEMSs sh-
owed no difference in the rate of pancreatitis.
32 Each 5-mm 
length bare meshed end of covered SEMSs allows embedding 
into the tissue to reduce the risk of migration. They were ori-
ginally introduced in an attempt to improve patency rates of 
covered SEMS compared to the uncovered SEMSs. However, 
non-randomized comparison studies comparing covered and 
uncovered Wallstents in unresectable distal malignant biliary 
obstruction did not show differences in stent patencies or com-
plication rates.
26,33 Two recent prospective randomized trials 
also failed to show a difference in stent patency between cover-
ed and uncovered SEMSs when they were placed endoscopi-
cally,
34,35 with an exception of one study of uncovered vs. non-
commercially available covered diamond stents.
36 Further well-
designed large scale randomized prospective studies are need-
ed to identify the benefits and indications of covered stents.JH Kim
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PALLIATION FOR MALIGNANT HILAR 
OBSTRUCTION
Resectability of malignant hilar obstructions should be ev-
aluated by imaging techniques in the absence of biliary stents. 
Palliative treatment in patients with unresectable malignant 
hilar obstruction clearly has an important role, because 80% of 
these are unresectable and a risk of recurrence is high even in 
those undergoing resection.
37,38 Being more difficult, requir-
ing higher degree of expertise, and carrying considerably hi-
gher morbidity and mortality rate, unresectable malignant hi-
lar obstruction represents a significantly greater challenge both 
technically and in decision making, than in malignant distal 
bile duct obstruction.
39 More than 90% of unresectable malig-
nant hilar obstructions have obstructive cholestasis and there-
fore restoration of bile flow is one of the main objectives of pal-
liative treatment.
40 A median survival of 6 to 9 months for un-
resectable hilar tumors implies that durable palliation should 
be one of the major objectives of treatment plan.
40 An ideal pal-
liative procedure should be simple and effective in relieving 
obstructive cholestasis, have low procedure-related morbidity 
and mortality, and offer durable palliation.
24 In general, when 
appropriate expertise is available, endoscopic palliation has 
been considered as the treatment of choice for palliation of 
unresectable malignant hilar obstruction, because it allows 
definitive internal drainage in single procedure. Combined per-
cutaneous and endoscopic procedures or percutaneous drain-
age alone are used in hilar tumors either after the failure of the 
endoscopic procedure or for further non-surgical interven-
tion where obstructive cholestasis fails to be resolved after the 
endoscopic procedure. Endoscopic biliary drainage can be achi-
eved with either plastic or metal stents, but patency rates of 
biliary stents are generally lower with malignant hilar obstruc-
tions, compared with malignant distal bile duct obstructions.
41 
The still remaining questions are whether to use one or multi-
ple stents, and plastic or metal stents for endoscopic palliation. 
Technique of endoscopic biliary stenting
One of the important technical considerations during bili-
ary stent insertion in malignant hilar obstruction, is that ini-
tially it is imperative not to inadvertently inject contrast me-
dium above the level of the hilar stricture into unintended mul-
tiple hepatic segments, because it frequently leads to postpro-
cedure cholangitis. Therefore, the hepatic segment(s) requir-
ing drainage should be carefully pre-selected before beginning 
ERCP with the aim of draining more than 50% of the liver vol-
ume in malignant hilar obstructions, based on an adequate 
cholangiogram obtained through either magnetic resonance 
(MR) or computed tomography (CT) scan.
42 Every effort is 
done to carefully inject contrast medium only into the obst-
ructed ducts that are intended to be drained, for example by 
injecting contrast medium after deep catheter insertion into 
the stricture of interest or by using contrast-free cannulation.
43,44 
The upstream bile duct(s) unintentionally opacified with con-
trast medium should be drained during the same procedure 
and antibiotics should be administered in case of suspected 
incomplete biliary drainage. Although no difference in effi-
cacy has been shown between single stent placement in the left 
or right hepatic lobe,
45 the left hepatic segments are drained 
preferentially if a single stent is to be placed. This is due to the 
longer length of the left main hepatic duct before branching, 
which leads to larger volumes of the liver being able to be dr-
ained, resulting in a more effective drainage than the right. 
Since the right system is more variable with earlier branching 
and multiple segment obstructions are more common, a right 
sided stent is more likely to drain only a limited portion. After 
a biliary stent is inserted, biliary balloon dilatation may be 
helpful for hilar strictures particularly when bilateral stenting 
is being attempted.
Bilateral stenting is technically challenging. The first stent is 
endoscopically placed in either the left or right hepatic duct 
whichever is more difficult to access first. The left stent is us-
ually placed first as it is more difficult to access compared to 
the right stent. There are two techniques for endoscopic pla-
cement of bilateral SEMSs; one is the ‘side-by-side’ (SBS) stent-
ing technique and the other is the ‘through-the-mesh’ (TTM) 
stenting or ‘stent-in-stent’ technique (Table 1). The SBS tech-
nique is an endoscopic procedure for bilateral plastic or metal 
stenting with sequential delivery of two or more parallel pla-
stic stents or SEMSs, to drain both intrahepatic bile ducts after 
multiple guidewire placements. It can be extremely difficult or 
unavailable despite best efforts in patients with unresectable 
hilar tumors. Once a SEMS is deployed endoscopically within 
the biliary tree, passaging a second SEMS alongside the ini-
tial stent is not technically easy because the first stent expands 
to completely occupy the bile duct lumen. So this technique 
usually demands prior dilatation. Strategies to overcome this 
difficulty for bilateral metal stenting include the following: 
SBS insertion of two delivery catheters (≤6 Fr) followed by 
simultaneous deployment of both SEMSs;
46 a rapid SEMS in-
sertion sequence, inserting the second SEMS assembly while 
the first SEMS is being deployed; having the first SEMS tra-
verse the papilla; or inserting a temporary plastic stent.
14,47 
On the other hand, the TTM technique is an alternative en-
doscopic procedure that allows bilateral metal stenting placed 
in a Y-configuration, in which a second stent traverses through 
the open-mesh wall of the initial stent to enter the opposite he-
patic lobe. During this procedure, attempts to pass a second 
metal stent through the mesh of the indwelling initial conven-
tional metal stent can be technically problematic, due to the 80  Clin Endosc 2011;44:76-86
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tightly woven structure of the stent wire mesh. Even if a taper-
tipped catheter, hydrostatic balloon, or a 7 Fr Soehendra stent 
extractor is used to widen the smaller-mesh wall of the initial 
stent, it is still proved difficult to permit passage of the second 
stent during an ERCP.
48 Strategies to facilitate this procedure 
include the following: balloon dilation of the contralateral he-
patic duct immediately before inserting the first stent to ease 
TTM cannulation of the contralateral duct; dilation of the 
cannulated first stent mesh by means of a balloon before in-
serting the second stent; or use of a specific SEMS with a wider 
mesh opening.
17
For overcoming such technical difficulty in the TTM techni-
que using conventional metal stents, several kinds of newly 
designed SEMSs have been recently introduced to facilitate 
passage of the second metal stent during bilateral stenting. One 
of them is a Y-stent (Y type biliary Niti-S stent; Taewoong Inc., 
Seoul, Korea) with a wider-mesh portion in the center and 
smaller-mesh portions on both ends.
49,50 The joining of the Y-
stent and conventional metal stent through the wider-mesh 
portion of the Y-stent produces a Y-shaped arrangement (Fig. 1). 
First Y-stent is endoscopically placed through the hilar stric-
ture into the intrahepatic bile duct, and then the second con-
ventional biliary metal stent is advanced over the guidewire 
from the inside of the Y-stent through the central wider-mesh 
portion into the contralateral intrahepatic duct, and released 
to form a Y-shape. The large opening in the wider-mesh wall 
of the first Y-stent permits easy passage of the delivery cathe-
ter for the second stent and its wide expansion (Fig. 2). More 
than two metal stents, including multiple Y-stents, can be in-
serted in sequence using the TTM technique in order to drain 
multiple hepatic segments. The two main drawbacks of this 
Y-stent are; first, later endoscopic access to both stents is often 
impossible after stent occlusion; secondly, the wider-mesh 
structure in the center causes an increasing tendency of tumor 
ingrowth and poor stent expansion due to the weak radical 
force. 
Other types of metal stents (M-Hilar stent and K-Hilar stent; 
Standard Sci-Tech Inc., Seoul, Korea) for bilateral stenting 
have been developed to overcome the drawbacks of the Y-st-
ent as described above.
51 The M-Hilar stent has been design-
ed with a differently woven structure in the center, which per-
mits easy passage of the delivery catheter of the second stent, 
even though it has no wider-mesh portion (Figs. 3, 4). The K-
Hilar stent is another special stent with a large hole in the cen-
ter of the stent (Figs. 5, 6). When this particular stent is used as 
the second stent during bilateral stenting, lumens of both stents 
are absolutely patent without blockage of the wire mesh. There-
Table 1. Comparison of the Results of Endoscopic Bilateral Metal Stenting with Through-the-Mesh Technique in Patients of Malignant Hilar 
Obstruction
Variable Lee et al. (2007)
49 Kawamoto et al. (2008)
52 Park et al. (2009)
51 Hwang et al. (2011)
50
Stent name Y-type Niti-S  JOSTENT SelfX M-Hilar Bona Y-type Niti-S
Number 10 41 35 30
Diagnosis
Cholangiocarcinoma 10 34 29 17
Gallbladder cancer 00 07 06 13
Bismuth classification
Type II 01 05 15 09
Type III 08 03 13 20
Type IV 01 33 07 01
Technical success rate, No. (%) 8/10 (80) 41/41 (100) 33/35 (94.3) 26/30 (86.7)
Functional success rate, No. (%) 008/8 (100)  39/41 (95.1) 33/33 (100). 26/26 (100).
Follow-up period, day 213 247
a) 142 176
Stent patency period, day 217 150
a) 150 140
Survival period, day NM 235
a) 180 176
NM, not mentioned.
a)Expressed as mean, others were expressed as median in follow-up period, stent patency period and survival period.
Fig. 1. Schema of ‘Through-the-mesh’ technique for endoscopic 
bilateral metal stenting using a Y-type biliary Niti-S stent. The join-
ing of the Y-stent with a wider-mesh portion in the center (left) and 
conventional metal stent (middle) through the wider-mesh portion 
of the Y-stent produces a Y-shaped arrangement (right).JH Kim
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fore, endoscopic re-intervention with plastic stents can be easily 
performed in cases where these new Y-stents were used.
Unilateral versus bilateral biliary stents
Single stents are adequate for Bismuth type I hilar tumors, 
which have strictures of the main bile duct below the conflu-
ence. However, there is significant controversy as to whether 
single or multiple stents should be inserted for Bismuth type 
II, III, and IV hilar tumors. The decision of whether to place 
single or multiple bilary stents depends on the location and 
extent of the stricture in the biliary tract as well as the degree 
of biliary contamination.
6 It is well known that only 25% of 
the liver volume needs to be drained for adequate palliation 
of obstructive cholestasis showing improvement in biochem-
ical parameters
11,53 and draining >50% of the liver volume is 
associated with a higher drainage effectiveness and longer 
survival than draining <50%.
17 A single biliary stent into one 
functional liver lobe for unilateral drainage can provide ade-
quate palliation in a major portion of patients with hilar tu-
mors, and many studies have reported good results using a 
single stent in about 80% of patients with Bismuth type II and 
III hilar tumors.
54,55
Sometimes, however, bilateral biliary stents may be needed 
for palliative drainage of both hepatic lobes when both sides 
Fig. 2. Endoscopic placement of bilateral metal stenting using a Y-type biliary Niti-S stent in patients with unresectable Bismuth type II ma-
lignant hilar obstruction. The first stent, being a Y-stent, was endoscopically placed in the left hepatic duct which is usually more difficult to ac-
cess first, and balloon dilatation was done to widen the opening of its central portion, thereafter a second stent, being a conventional biliary metal 
stent, was inserted through the open-mesh wall of the first stent to gain access to the opposite hepatic lobe, resulting in a Y-configuration.82  Clin Endosc 2011;44:76-86
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are contaminated, when a non-dominant or atrophic lobe was in-
advertently stented without efficacy, or if bilateral brachyth-
erapy is scheduled.
56 Especially the vigorous opacification of 
multiple bile ducts of both hepatic lobes, to obtain detailed 
cholangiograms with contrast during ERCP, increases the ne-
cessity for bilateral stent insertion in hilar tumors, because ch-
olangitis mainly arises from contaminated and undrained bile 
ducts. Drainage of both systems during ERCP is actually to 
prevent postprocedure cholangitis rather than to have effective 
palliation. If both lobes are imaged with contrast during ERCP, 
bilateral stent insertion reduces the potential sequelae of chol-
angitis in undrained bile ducts. However, even in the most 
experienced hands, endoscopic placement of bilateral stents 
may be difficult or impossible, and failure of bilateral stenting 
Fig. 4. Endoscopic placement of bilateral metal stenting using a biliary M-Hilar stent in patients with unresectable Bismuth type IIIa malignant 
hilar obstruction. The first stent, being M-Hilar stent, was endoscopically placed in the left intrahepatic bile duct, and the second stent, being a con-
ventional biliary metal stent, was inserted through the differently woven structure in the center of the first stent to gain access to the right hepatic 
lobe, resulting in a Y-configuration.
Fig. 3. ‘Through-the-mesh’ technique for endoscopic bilateral metal stenting using a biliary M-Hilar stent. The M-Hilar stent has been designed 
with a differently woven structure in the center (left upper, noted portion), which permits easy passage of the delivery catheter of the second 
stent, even though it has no wider-mesh portion. The joining of both stents through the central-mesh portion of the M-Hilar stent produces a 
Y-shaped arrangement.JH Kim
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after extensive contaminated contrast filling of multiple bile 
ducts may frequently lead to subsequent cholangitis. If con-
trast medium does not contaminate both sides or is sufficient-
ly drained from unilateral bile duct after imaging both sides, 
then unilateral stenting should be enough and is substantially 
easier to perform endoscopic re-intervention.
Several studies have attempted to address whether unilateral 
or bilateral drainage is preferred for palliation of obstructive 
jaundice in patients with hilar tumors.
5,55,57,58 Early studies have 
shown high rates of cholangitis following ERCP in large parts 
attributed to the contamination of the undrained segments 
which was caused by contrast injection without any planned 
limitations.
5,57 These studies showed that bilateral stent inser-
tion was associated with an increased survival rate and reduced 
risk of cholangitis, compared to unilateral drainage for Bis-
muth type II and III hilar tumors.
57 The highest survival rate 
was noted in patients with hilar tumors who had bilateral dr-
ainage, while the lowest survival rate in those who showed 
cholangiographic opacification of both lobes but only unilat-
eral drainage was available.
5 These results are believed to 
have been caused by inadvertent contrast injections into the 
undrained bile ducts and quite clearly show that failure to 
drain an opacified lobe leads to a significantly negative out-
come, thus bilateral drainage being mandatory if both hepatic 
lobes are opacified. However, an unsuccessful attempt at bi-
lateral drainage can lead to increased incidence of postproce-
dure cholangitis and lower survival rates.
44,54 Therefore, ERCP 
in hilar tumors should only be undertaken in highly regarded 
Fig. 5. ‘Through-the-mesh’ technique for endoscopic bilateral metal 
stenting using a biliary K-Hilar stent. The K-Hilar stent is a special 
stent with a large hole in the center of the stent (middle). When this 
particular stent is used as the second stent during bilateral stenting, 
lumens of both stents are absolutely patent without blockage of 
the wire mesh. The joining of both biliary M-Hilar stent (left) and K-
Hilar stent through the central-mesh portion of the M-Hilar stent (left, 
noted portion) produces a Y-shaped arrangement (right).
Fig. 6. Endoscopic placement of bilateral metal stenting using two biliary K-Hilar stents in a patient with unresectable Bismuth type IIIa ma-
lignant hilar obstruction. The first K-Hilar stent was endoscopically placed in the left intrahepatic bile duct, and the second K-Hilar stent was 
inserted through the large hole in the center of the first stent to gain access to the opposite hepatic lobe, resulting in a Y-configuration.84  Clin Endosc 2011;44:76-86
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institutions with high success rates for drainage of hilar ob-
struction. 
Selectively targeted and planned endoscopic drainage gu-
ided by MR cholangiography or CT imaging has recently been 
introduced to reduce inadvertent contrast injections into at-
rophied and/or unintended multiple hepatic segments, result-
ing in a lower incidence of postprocedure cholangitis.
15,44,55,58,59 
MR findings seem to be slightly more accurate than CT find-
ings in assessing the level of obstruction in malignant hilar ob-
structions and measuring the volume of functional liver lobes. 
MR cholangiography is widely known as a reliable and nonin-
vasive diagnostic tool and shows equivalent imaging to that 
of ERCP in demonstrating the detailed anatomy of the biliary 
tree. Several advantages of MR cholangiography over ERCP 
include noninvasive diagnostic tool, no use of contrast medi-
um and the delineation of missing ducts which are not visible 
on the endoscopic cholangiogram due to complete obstruction 
of the bile ducts. Cholangiograms obtained from MR provide 
a road map for the biliary endoscopist to define the biliary 
anatomy prior to ERCP, and allow them to choose the optimal 
hepatic lobe and bile ducts for effective drainage.
15,44,55,58 Now-
adays MR cholangiography has led to the unnecessary need 
for a diagnostic ERCP and is rapidly replacing its role for the 
delineation of the biliary tree, therefore ERCP is becoming an 
unnecessary procedure for such diagnostic purposes in hilar 
tumors. ERCP for hilar obstruction can be undertaken mainly 
for the therapeutic purpose of endoscopic intervention such as 
stenting into the targeted bile duct with the help of MR chol-
angiography. Several studies have evaluated the role of MR-
guided selective unilateral biliary stent placement for endo-
scopic palliation of hilar tumors, and showed that the use of 
MR cholangiography to plan a layout of the intended endosco-
pic placement of the stent, reduced the need to inject contrast 
medium into multiple segments during ERCP, and thus di-
minished the risk of postprocedure cholangitis.
44,58-60
Plastic versus metal biliary stents
A plastic stent has been commonly used to achieve biliary 
drainage in patients with a malignant hilar obstruction. How-
ever, the use of plastic stents for the palliation of hilar tumors 
revealed poor results in some series.
56,61 Plastic stents in the hi-
lar stricture have limited stent patency due to their narrow lu-
men and a higher chance of stent clogging due to the longer 
length of the stent used. Stent occlusion frequently results in 
cholangitis with rates as high as 20% to 40% reported for un-
ilateral or bilateral plastic stents due to bacterial contamination 
of undrained bile ducts.
56,61 Other disadvantages of plastic 
stents include that it is technically difficult to place more than 
one 10 Fr stent at the initial setting and plastic stents in hilum 
are prone to distal migration.
6 
SEMSs are increasingly favored, although individually 
more expensive. A larger diameter of SEMSs may potentially 
result in improved stent patency as compared with that of pla-
stic stents, thus requiring fewer repeated procedures.
20,60,62 In 
addition, there are some theoretical advantages of metal stents 
in hilar tumors, including the open-mesh design, which allows 
drainage of secondary branches through the side of the stent 
and less likelihood of obstructive segmental cholangitis.
63 
When single lobe drainage is planned, insertion of an uncov-
ered metal stent is preferred to prolong patency, and to avoid 
occlusion of branch ducts which is more likely with a plastic 
stent. Although little data is available on hilar tumors, the cur-
rent evidence favors the placement of SEMSs as they provide 
a superior palliation in comparison to plastic stents in terms 
of early and late complications.
5,64 Insertion of SEMS is espe-
cially recommended in patients with a life expectancy of >3 
months or with biliary infection. The initial higher cost is off-
set by lower incidence of re-intervention and hospitalization for 
complications.
61 However, a major limiting factor of SEMSs is 
that they cannot be removed other than surgically.
24 So plastic 
stent placement for the palliative therapy can be recommend-
ed if diagnosis is clinically ambiguous or SEMS placement is 
impossible. Covered metal stents are not appropriate for hilar 




Palliative management of patients with unresectable ma-
lignant biliary obstructions is challenging for all biliary special-
ists, because there is no single correct approach for it and there 
are several controversies in choice of therapies according to the 
location and extension of tumors. For palliation of malignant 
distal bile duct obstructions, an endoscopic approach should 
be initially used with percutaneous radiological intervention 
reserved for its failures. For palliation of malignant hilar ob-
structions, the endoscopic approach has also been considered 
as the treatment of choice when performed by an appropriate 
expertise, although percutaneous approaches may vary de-
pending on the institution. There is still a lack of clear consen-
sus on the use of covered versus uncovered metal stents in 
malignant distal bile duct obstructions and plastic versus 
metal stents and unilateral versus bilateral drainage in malig-
nant hilar obstructions. This decision should be made on an 
individual basis, till acceptable results are found in random-
ized, controlled trials further evaluating these therapies. For 
future advanced biliary stents, drug-eluting SEMSs would par-
ticularly be appealing for the treatment of malignant biliary 
obstruction although they are not commercially available for 
biliary use yet, and currently radioactive SEMS and bioabsorb-JH Kim
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able self-expanding stents are being tested in animal models.
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